|Articles|January 1, 2003
Federal investigators seek tighter regulation of drug advertising
Washington, D.C. - Direct-to-consumer (DTC) advertising of prescription drugs is growing and is boosting spending on pharmaceuticals, so the Food and Drug Administration (FDA) needs to pick up the pace to remove false or misleading commercials from the air. Those are the main conclusions of a landmark report on DTC advertising from Congress' General Accounting Office ("FDA Oversight of Direct-to-Consumer Advertising Has Limitations," available at www.gao.gov).
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Drug Pricing Not Main Driver of State Medicaid Spending | AMCP Nexus 2025
2
Real-World Study Shows $330,000 Cost Difference Between CAR T and BiTE Therapies | AMCP Nexus 2025
3
PBM Reform Debate: Panelists Clash Over Spread Pricing and Rebates | AMCP Nexus 2025
4
Generalized Anxiety Disorder Affects More Than One in Ten U.S. Adults | AMCP Nexus 2025
5














































